Zacks: Analysts Anticipate Tandem Diabetes Care Inc (TNDM) Will Announce Earnings of -$0.49 Per Share

Wall Street brokerages expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to announce earnings per share (EPS) of ($0.49) for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Tandem Diabetes Care’s earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.37). Tandem Diabetes Care reported earnings per share of ($0.60) during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.3%. The company is scheduled to issue its next quarterly earnings results on Thursday, July 27th.

On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($2.60) to ($1.46). For the next financial year, analysts forecast that the company will post earnings of ($1.29) per share, with EPS estimates ranging from ($2.18) to ($0.76). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, April 27th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.09. The firm had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $15.72 million. Tandem Diabetes Care had a negative return on equity of 220.14% and a negative net margin of 95.57%. The business’s revenue for the quarter was down 12.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.68) EPS.

TNDM has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Tuesday, March 14th. Northcoast Research restated a “buy” rating on shares of Tandem Diabetes Care in a research note on Thursday, March 9th. B. Riley restated a “buy” rating and issued a $5.00 target price on shares of Tandem Diabetes Care in a research note on Saturday, March 11th. Cowen and Company lowered shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 target price on the stock. in a research note on Monday, April 10th. Finally, Piper Jaffray Companies restated a “neutral” rating on shares of Tandem Diabetes Care in a research note on Thursday, March 30th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $4.71.

In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff acquired 1,600,000 shares of the stock in a transaction that occurred on Thursday, March 23rd. The stock was acquired at an average price of $1.25 per share, with a total value of $2,000,000.00. Following the transaction, the chief executive officer now directly owns 2,007,939 shares in the company, valued at $2,509,923.75. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 37.10% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. Frontier Capital Management Co. LLC increased its stake in shares of Tandem Diabetes Care by 348.5% in the first quarter. Frontier Capital Management Co. LLC now owns 4,901,870 shares of the medical device company’s stock worth $5,882,000 after buying an additional 3,808,950 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 181.1% in the first quarter. Vanguard Group Inc. now owns 1,200,616 shares of the medical device company’s stock worth $1,441,000 after buying an additional 773,475 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Tandem Diabetes Care during the first quarter worth $600,000. Bank of America Corp DE increased its stake in shares of Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Tandem Diabetes Care during the first quarter worth $360,000. 56.79% of the stock is owned by institutional investors and hedge funds.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded up 0.7366% during trading on Friday, hitting $0.9163. The company’s stock had a trading volume of 115,045 shares. The company’s market cap is $45.67 million. Tandem Diabetes Care has a 52 week low of $0.87 and a 52 week high of $8.81. The firm’s 50 day moving average price is $1.04 and its 200-day moving average price is $1.98.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate Tandem Diabetes Care Inc (TNDM) Will Announce Earnings of -$0.49 Per Share” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/06/16/zacks-analysts-anticipate-tandem-diabetes-care-inc-tndm-will-announce-earnings-of-0-49-per-share-updated-updated-updated.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

5 Day Chart for NASDAQ:TNDM

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply